Announcements
- argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
- argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
- argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
- argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
- argenx Appoints Ana Cespedes to Board of Directors
- argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
- argenx Enters Into Agreement To Acquire Priority Review Voucher
- argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
- argenx to Present at Upcoming Investor Conferences
- argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
More ▼
Key statistics
On Tuesday, argenx SE (ARGXN:MEX) closed at 7,342.15, 0.00% below its 52-week high of 7,342.15, set on Oct 04, 2022.
52-week range
Markit short selling activity
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 7,342.15 |
Average volume | -- |
---|---|
Shares outstanding | 55.47m |
Free float | 54.74m |
P/E (TTM) | -- |
Market cap | 20.78bn USD |
EPS (TTM) | -17.47 USD |
Data delayed at least 20 minutes, as of Oct 04 2022 12:30 BST.
More ▼